ClinicalTrials.gg
RecruitingNCT06028139Updated Apr 17, 2024

Health Coaching, Continuous Glucose Monitoring and AI Mobile App in Diabetes

An interventional study of Continuous glucose monitoring and health coaching and EMPOWER mobile app in Diabetes Mellitus, Type 2, sponsored by Singapore General Hospital. Recruiting at 3 sites in Singapore. Open to participants aged 21 Years to 100 Years. Per ClinicalTrials.gov, last updated 2024-04-17.

Sponsored by Singapore General Hospital · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2024, 1 year 11 months ago, but the record still lists the study as recruiting.
  • Started Oct 2023; still recruiting 3 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
400
Allocation
Randomized
Ages
21 Years to 100 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 15 studies in Diabetes Mellitus, Type 2 by Singapore General Hospital — 5 open to participants now, 8 under way, none of them phase 3. Diabetes Mellitus, Type 2 · Singapore General Hospital.

Planned enrollment
3rd of 13
400 · median 150
Started
2023
with 2 others
No phase
13 of 15
5 open now
Registered
12th of 15
by date

Among the 15 studies in Diabetes Mellitus, Type 2 by Singapore General Hospital, this one is the 3rd largest by planned enrollment of the 13 interventional ones that give a count, is one of 3 that started in 2023, is one of 13 with no phase, and was the 12th registered.

Diabetes Mellitus, Type 2

10,403 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

5 of the 15 studies in Diabetes Mellitus, Type 2 by Singapore General Hospital are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

Who these studies take

Of the 882 Diabetes Mellitus, Type 2 studies recruiting now, 372 (42%) set no upper age limit and 384 (44%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.

This study: 21 Years to 100 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in Diabetes Mellitus, Type 2 by Singapore General Hospital, or all of them as a file.
02

Study summary

Lifestyle change is key to diabetes management but there are limited resources and time to support patients in improving lifestyle behaviour in the current healthcare system. Currently, health coaching for behavioural chance guided by continuous glucose data, wearable and lifestyle data is not available in primary and tertiary care management of diabetes. This parallel-group randomised controlled trial (RCT) aims to investigate the effectiveness of a novel multi-component model of care comprising interventions including the mobile app EMPOWER and smartwatch, health coaching, and continuous glucose monitoring (CGM).

03

Conditions studied

  • Diabetes Mellitus, Type 2
04

Who can participate

Ages eligible
21 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged 21 years and above
  • Have diagnosis of type 2 diabetes mellitus
  • Provided
  • Have near-field communication (NFC) compatible phones
  • Able to engage in light physical activity (e.g., walking)

Exclusion criteria

Exclusion Criteria:

  • Significant cognitive impairment
  • Other conditions that may preclude participants from wearing CGM devices
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
400 participants (estimated)

Study arms

  • Experimental
    Intervention

    Behavioral: Continuous glucose monitoring and health coaching · Behavioral: EMPOWER mobile app

  • Other
    Control

    Behavioral: EMPOWER mobile app

Interventions

  • BehavioralContinuous glucose monitoring and health coaching

    Each CGM device will work for 14 days. The participants will use the CGM devices for the first two-week period in the first three months of the trial, and the first two-week period of the second three months of the trial. Participants will interact with health coach throughout the study duration.

  • BehavioralEMPOWER mobile app

    Nudges will be delivered through the EMPOWER mobile app. Participants will log lifestyle information such as diet and physical activity, and clinical information such as medication and HbA1c levels through the EMPOWER mobile app.

06

What researchers measure

Primary outcomes

  1. HbA1c

    HbA1c over 6 months

    Time frame: 6 months

Secondary outcomes

  1. Physical activity as measured by number of steps

    Physical activity over 6 months

    Time frame: 6 months

  2. Physical activity as measured by moderate to vigorous active minutes

    Physical activity over 6 months

    Time frame: 6 months

  3. Physical activity as measured by GPAQ

    Physical activity over 6 months

    Time frame: 6 months

  4. Diet as measured by DASH

    Diet quality over 6 months

    Time frame: 6 months

  5. Sugar sweetened beverages intake

    Sugar sweetened beverages intake over 6 months

    Time frame: 6 months

  6. Patient activation score as measured by patient activation measure

    Difference in patient activation score between intervention and control over 6 months

    Time frame: 6 months

  7. Medication adherence as measured by DOSE-Nonadherence scale

    Difference in medication adherence between intervention and control over 6 months

    Time frame: 6 months

  8. Quality of life as measured by EQ-5D-5L

    Difference in quality of life between intervention and control over 6 months

    Time frame: 6 months

  9. Healthcare cost as measured by cost of consultations, lab tests, medications, admission

    Healthcare cost over 6 months

    Time frame: 6 months

  10. Healthcare cost as measured by WPAI

    Healthcare cost over 6 months

    Time frame: 6 months

07

Study locations

3 of 3 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2023 (actual). Primary completion is estimated for Dec 2024, 14 months after the start.

Of 2,078 non-industry interventional studies with no phase under Diabetes Mellitus, Type 2, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 40. This study's planned 14 months is below that.

Counting every sponsor, half of 2,255 studies reached it within 21 months; a quarter within 10 and three quarters within 39.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 28, 2023
First posted
Sep 8, 2023
StartActual
Oct 24, 2023
Primary completionEst.
Dec 2024
CompletionEst.
Dec 2024
Last update
Apr 17, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 17, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06028139
Collaborators
Sengkang General Hospital, National Heart Centre Singapore
Responsible party
Sponsor
First posted
Sep 8, 2023
Start date
Oct 24, 2023
Primary completion
Dec 2024 (estimated)
Completion
Dec 2024 (estimated)
Last update
Apr 17, 2024

Study contacts

Lian Leng Low
Contact
low.lian.leng@singhealth.com.sg
63265872

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion